We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Novartis (NVS) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Novartis (NVS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of NVS and the rest of the Medical group's stocks.
Novartis is one of 866 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. NVS is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for NVS's full-year earnings has moved 2.96% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, NVS has moved about 3.16% on a year-to-date basis. At the same time, Medical stocks have gained an average of 1.71%. This means that Novartis is outperforming the sector as a whole this year.
Looking more specifically, NVS belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual stocks and currently sits at #29 in the Zacks Industry Rank. On average, stocks in this group have gained 1.81% this year, meaning that NVS is performing better in terms of year-to-date returns.
NVS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Novartis (NVS) Outpaced Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Novartis (NVS - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of NVS and the rest of the Medical group's stocks.
Novartis is one of 866 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. NVS is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for NVS's full-year earnings has moved 2.96% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, NVS has moved about 3.16% on a year-to-date basis. At the same time, Medical stocks have gained an average of 1.71%. This means that Novartis is outperforming the sector as a whole this year.
Looking more specifically, NVS belongs to the Large Cap Pharmaceuticals industry, a group that includes 14 individual stocks and currently sits at #29 in the Zacks Industry Rank. On average, stocks in this group have gained 1.81% this year, meaning that NVS is performing better in terms of year-to-date returns.
NVS will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.